Edesa Biotech, Inc.
(NASDAQ : EDSA)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
PFEPfizer Inc. -0.25%40.000.9%$1281.75m
JNJJohnson & Johnson 0.14%170.190.7%$1253.43m
MRKMerck & Co., Inc. -0.60%78.220.7%$926.88m
ABBVAbbVie, Inc. -0.07%116.521.9%$721.02m
BMYBristol-Myers Squibb Co. -0.31%64.841.0%$719.56m
LLYEli Lilly & Co. 0.75%196.401.1%$573.53m
AZNAstraZeneca Plc 0.29%55.211.2%$531.67m
BTXBrooklyn ImmunoTherapeutics, Inc. -7.43%21.6912.8%$256.18m
GSKGlaxoSmithKline Plc 1.11%39.090.2%$191.43m
NVSNovartis AG 0.68%89.000.2%$173.64m
VTRSViatris, Inc. 0.44%16.000.0%$168.43m
CVACCureVac NV 7.47%109.990.0%$159.75m
NVONovo Nordisk A/S 0.28%79.110.1%$72.19m
SNYSanofi 0.38%52.740.2%$71.76m
ATNXAthenex, Inc. 3.25%5.080.0%$62.70m

Company Profile

Edesa Biotech, Inc. is a biopharmaceutical company, which focuses on acquiring, developing and commercializing clinical stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. The company product candidate, EB01 is a non-steroidal, anti-inflammatory treatment for chronic allergic contact dermatitis (ACD), a common, potentially debilitating condition and occupational illness. EB01 employs a novel, non-steroidal mechanism of action and in two clinical studies has demonstrated statistically significant improvement of multiple symptoms in ACD patients. Edesa Biotech was founded on June 12, 2007 and is headquartered in Markham, Canada.